Medicamen Biotech Ltd. | Small-cap | Healthcare
₹353.40
0.11%
| Medicamen Biotech Stock Comparison:
Medicamen Biotech vs Sun PharmaceuticalMedicamen Biotech vs Divi's LaboratoriesMedicamen Biotech vs Sun Pharma AdvancedMedicamen Biotech vs Aarti DrugsMedicamen Biotech vs Sequent ScientificMedicamen Biotech vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 296.1M
Gross Profit 158.5M 53.52%
Operating Income -20.9M -7.05%
Net Income 18.6M 6.29%

Balance Sheet Metrics

Total Assets 3.0B
Total Liabilities 841.0M
Shareholders Equity 2.1B
Debt to Equity 0.40

Cash Flow Metrics

Revenue & Profitability Trend

Medicamen Biotech Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i1.6B1.8B1.4B1.2B1.1B
Cost of Goods Sold i846.2M926.0M859.9M674.6M792.0M
Gross Profit i779.3M867.1M548.8M479.9M335.2M
Gross Margin % i47.9%48.4%39.0%41.6%29.7%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i--82.7M77.2M41.5M
Other Operating Expenses i322.0M344.0M3.0M4.6M3.9M
Total Operating Expenses i322.0M344.0M85.7M81.8M45.4M
Operating Income i67.9M151.5M188.9M190.0M171.5M
Operating Margin % i4.2%8.4%13.4%16.5%15.2%
Non-Operating Items
Interest Income i-7.2M7.2M1.4M1.5M
Interest Expense i31.6M44.0M29.2M14.0M10.6M
Other Non-Operating Income-----
Pre-tax Income i98.8M130.8M170.4M180.9M163.9M
Income Tax i33.2M35.8M23.2M32.0M42.6M
Effective Tax Rate % i33.6%27.4%13.6%17.7%26.0%
Net Income i65.6M94.9M147.3M149.0M121.3M
Net Margin % i4.0%5.3%10.5%12.9%10.8%
Key Metrics
EBITDA i201.1M244.9M272.3M259.4M199.7M
EPS (Basic) i₹5.16₹8.63₹11.73₹12.19₹9.93
EPS (Diluted) i₹5.16₹8.63₹11.73₹12.19₹9.93
Basic Shares Outstanding i1377558112659277126511001221660012216600
Diluted Shares Outstanding i1377558112659277126511001221660012216600

Income Statement Trend

Medicamen Biotech Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i37.6M147.9M207.8M38.2M38.9M
Short-term Investments i-----
Accounts Receivable i689.0M552.6M652.6M632.2M525.5M
Inventory i621.4M593.8M450.6M270.1M52.0M
Other Current Assets266.6M256.8M-1.0K237.2M272.5M
Total Current Assets i1.6B1.6B1.6B1.2B960.3M
Non-Current Assets
Property, Plant & Equipment i861.2M192.7M173.3M158.7M140.9M
Goodwill i7.4M9.0M9.0M3.6M2.0M
Intangible Assets i7.4M9.0M9.0M3.6M2.0M
Long-term Investments-----
Other Non-Current Assets414.2M393.7M195.1M88.2M75.6M
Total Non-Current Assets i1.3B1.3B1.2B1.0B976.9M
Total Assets i3.0B2.9B2.8B2.3B1.9B
Liabilities
Current Liabilities
Accounts Payable i426.0M367.0M431.7M433.0M322.1M
Short-term Debt i295.2M298.6M248.4M207.2M124.1M
Current Portion of Long-term Debt-----
Other Current Liabilities19.3M81.5M39.8M20.3M400.0K
Total Current Liabilities i781.7M845.6M825.7M726.9M532.7M
Non-Current Liabilities
Long-term Debt i37.3M12.6M8.7M50.7M64.0M
Deferred Tax Liabilities i-31.0K0000
Other Non-Current Liabilities6.0K-1.0K-1.0K1.0K
Total Non-Current Liabilities i59.4M30.1M25.3M65.3M75.6M
Total Liabilities i841.0M875.7M851.0M792.2M608.3M
Equity
Common Stock i127.1M127.1M126.5M122.2M122.2M
Retained Earnings i-907.7M825.4M687.8M551.1M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i2.1B2.1B1.9B1.5B1.3B
Key Metrics
Total Debt i332.5M311.1M257.1M258.0M188.2M
Working Capital i863.8M750.4M807.9M503.5M427.6M

Balance Sheet Composition

Medicamen Biotech Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i65.5M94.9M147.3M149.0M121.3M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-258.2M-153.6M-288.7M-250.9M25.1M
Operating Cash Flow i-166.0M-21.9M-119.4M-89.3M155.5M
Investing Activities
Capital Expenditures i-20.7M-62.9M-66.0M-86.1M-179.7M
Acquisitions i-----
Investment Purchases i-3.0M0000
Investment Sales i-----
Investing Cash Flow i-23.8M-62.9M-66.0M-86.1M-179.7M
Financing Activities
Share Repurchases i-----
Dividends Paid i-12.7M-12.7M-12.7M-12.2M-6.1M
Debt Issuance i16.7M3.9M--40.5M
Debt Repayment i-430.0K--42.0M-13.3M-
Financing Cash Flow i11.7M107.1M324.6M57.0M69.0M
Free Cash Flow i-92.7M-130.3M-128.9M-45.0M-51.9M
Net Change in Cash i-178.1M22.3M139.3M-118.4M44.9M

Cash Flow Trend

Medicamen Biotech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 68.54
Price to Book 2.11
Price to Sales 2.96

Profitability Ratios

Profit Margin 4.37%
Operating Margin -7.05%
Return on Equity 3.12%
Return on Assets 1.44%

Financial Health

Current Ratio 2.10
Debt to Equity 15.63
Beta 0.63

Per Share Data

EPS (TTM) ₹5.15
Book Value per Share ₹167.35
Revenue per Share ₹127.84

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
medicameq4.8B68.542.113.12%4.37%15.63
Sun Pharmaceutical 3.9T37.885.4515.08%19.29%3.26
Divi's Laboratories 1.6T70.4210.8814.64%23.89%0.03
Sun Pharma Advanced 45.5B-13.34-21.04157.88%-53.22%-1.24
Aarti Drugs 44.4B23.593.2512.28%7.80%44.92
Sequent Scientific 43.9B154.186.242.84%1.85%62.47

Financial data is updated regularly. All figures are in the company's reporting currency.